Filippi Massimo, Grossman Robert I
Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy.
Neurology. 2002 Apr 23;58(8):1147-53. doi: 10.1212/wnl.58.8.1147.
Conventional MRI (cMRI) is limited in its ability to provide specific information about pathology in MS. Measures commonly derived from cMRI include T2 lesions, T1-enhanced lesions, atrophy, and possibly T1-hypointense lesions, which have been extensively investigated in many clinical trials. Better MRI measures are needed to advance our understanding of MS and design ideal clinical trials. This article reviews the strengths and weaknesses of the major MRI-based methods used to monitor MS evolution and submits that 1) metrics derived from magnetization transfer MRI, diffusion-weighted MRI, and proton MRS should be implemented to achieve reliable specific in vivo quantification of MS pathology; 2) targeted multiparametric MRI protocols rather than generic application of cMRI should be used in all possible clinical circumstances and trials; and 3) reproducible quantitative MR measures should ideally be used for the assessment of patients but are essential for clinical trials.
传统磁共振成像(cMRI)在提供有关多发性硬化症(MS)病理学的特定信息方面能力有限。通常从cMRI得出的测量指标包括T2病变、T1强化病变、萎缩,以及可能的T1低信号病变,这些在许多临床试验中都已得到广泛研究。需要更好的磁共振成像测量方法来增进我们对MS的理解并设计理想的临床试验。本文回顾了用于监测MS进展的主要基于磁共振成像方法的优缺点,并提出:1)应采用源自磁化传递磁共振成像、扩散加权磁共振成像和质子磁共振波谱的指标,以实现对MS病理学进行可靠的体内特异性定量;2)在所有可能的临床情况和试验中,应使用针对性的多参数磁共振成像方案,而不是一般应用的cMRI;3)理想情况下,应使用可重复的定量磁共振测量来评估患者,但这对临床试验至关重要。